KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $5,232,420 | +69.3% | 2,207,772 | 0.0% | 6.23% | +30.2% |
| Q3 2023 | $3,090,881 | -53.8% | 2,207,772 | 0.0% | 4.78% | -45.2% |
| Q2 2023 | $6,689,549 | -51.5% | 2,207,772 | 0.0% | 8.73% | -53.7% |
| Q1 2023 | $13,798,575 | +2.5% | 2,207,772 | 0.0% | 18.88% | +4.3% |
| Q4 2022 | $13,467,409 | -49.0% | 2,207,772 | 0.0% | 18.10% | -23.6% |
| Q3 2022 | $26,383,000 | -23.8% | 2,207,772 | -19.6% | 23.68% | -19.1% |
| Q2 2022 | $34,645,000 | +12.0% | 2,747,433 | 0.0% | 29.28% | +62.7% |
| Q1 2022 | $30,936,000 | -36.5% | 2,747,433 | 0.0% | 17.99% | -1.2% |
| Q4 2021 | $48,685,000 | -23.0% | 2,747,433 | 0.0% | 18.21% | +0.5% |
| Q3 2021 | $63,246,000 | -1.1% | 2,747,433 | 0.0% | 18.11% | +13.0% |
| Q2 2021 | $63,960,000 | -25.3% | 2,747,433 | 0.0% | 16.04% | -25.8% |
| Q1 2021 | $85,610,000 | -21.7% | 2,747,433 | +0.0% | 21.63% | -3.6% |
| Q4 2020 | $109,279,000 | – | 2,747,074 | – | 22.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $225,156,000 | 30.44% |
| Vida Ventures Advisors, LLC | 2,747,433 | $63,960,000 | 16.04% |
| Foresite Capital Management V, LLC | 875,001 | $20,370,000 | 8.01% |
| VR Adviser, LLC | 1,473,014 | $34,292,000 | 4.16% |
| Logos Global Management LP | 1,329,602 | $30,953,000 | 2.60% |
| RA Capital Management | 3,593,052 | $83,646,000 | 1.34% |
| Orbimed Advisors | 3,847,929 | $89,580,000 | 0.91% |
| Boxer Capital, LLC | 1,065,939 | $24,815,000 | 0.88% |
| HARVARD MANAGEMENT CO INC | 498,001 | $11,593,000 | 0.67% |
| HighVista Strategies LLC | 33,391 | $777,000 | 0.55% |